scholarly journals Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence

2021 ◽  
Vol 13 (8) ◽  
pp. 916-925
Author(s):  
Prajna Anirvan ◽  
Shivaram P Singh ◽  
Alexa Giammarino ◽  
Sanjaya K Satapathy
Keyword(s):  
Liver Disease ◽  
Literature Review ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Current Evidence ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

2017 ◽  
Vol 26 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Ahmed Elgebaly ◽  
Ibrahim A. I. Radwan ◽  
Mohamed M. AboElnas ◽  
Hamza H. Ibrahim ◽  
Moutaz F. M. Eltoomy ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Randomized Clinical Trials ◽  
Controlled Trial ◽  
Antioxidant Properties ◽  
Density Lipoprotein ◽  
Current Evidence ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

An Evidence-based Study on Pharmacological Treatments of Non-Alcoholic Fatty Liver Disease Based on Traditional Persian Medicine

2020 ◽  
Vol 6 (3) ◽  
pp. 188-202
Author(s):  
Fatemeh Sadat Hasheminasab ◽  
Haleh Tajadini ◽  
Mohammad Setayesh
Keyword(s):  
Liver Disease ◽  
Medicinal Plants ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Current Evidence ◽  
Evidence Based ◽  
Alcoholic Fatty Liver ◽  
Persian Medicine ◽  
Traditional Persian Medicine ◽  
Alcoholic Fatty Liver Disease

Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent liver diseases regarded as the primary cause of chronic liver disease, which may lead to hepatic failure. Despite the recent developments in the treatment of NAFLD, the necessity to find more efficient treatments has led to investigation on medicinal plants. Traditional Persian Medicine (TPM) is one of the oldest medical schools in the world. For treatment of NAFLD, different medicinal plants have been employed in TPM. Objective: Considering the public welcome for herbal medicines, the current evidence-based review study is conducted to investigate herbal remedies for NAFLD in TPM. Methods: Medicinal plants for treating NFALD were extracted according to three famous textbooks of Persian medicine. Then anti-obesity, hypolipidemic, hypoglycemic, antioxidative and hepatoprotective effects of these medicinal plants were investigated according to modern medicine. For this purpose, databases including Scopus, web of sciences, Pubmed, Google scholar and science direct were searched. Results: Investigations of Persian medicine textbooks resulted in deriving 53 herbs, which are useful for treating NAFLD. Searching through aforesaid databases showed that most of these plants can help to treat this disease in at least 2 ways. 25 herbs are effective in all 5 mentioned effects. Conclusion: It should be considered that in Persian medicine, first-line treatment is correction of life style, then if necessary, herbs are prescribed. However, this study showed that many herbs mentioned in Persian medicine for treatment of NAFLD might have a potential to aid patient with this disease.

scholarly journals Statins in Non-alcoholic Steatohepatitis

2021 ◽  
Vol 8 ◽  
Author(s):  
Jose D. Torres-Peña ◽  
Laura Martín-Piedra ◽  
Francisco Fuentes-Jiménez
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Dynamic Condition ◽  
Current Evidence ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Steatohepatitis ◽  
Relevant Role ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, diabetes, and dyslipidemia. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins exert anti-inflammatory, proapoptotic, and antifibrotic effects. It has been proposed that these drugs could have a relevant role in NASH. In this review, we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat or attenuate NASH.

scholarly journals Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 4077
Author(s):  
José Ignacio Martínez-Montoro ◽  
Isabel Cornejo-Pareja ◽  
Ana María Gómez-Pérez ◽  
Francisco J. Tinahones
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Dietary Habits ◽  
Individual Variability ◽  
Response To Therapy ◽  
Current Evidence ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

In the last decades, the global prevalence of non-alcoholic fatty liver disease (NAFLD) has reached pandemic proportions with derived major health and socioeconomic consequences; this tendency is expected to be further aggravated in the coming years. Obesity, insulin resistance/type 2 diabetes mellitus, sedentary lifestyle, increased caloric intake and genetic predisposition constitute the main risk factors associated with the development and progression of the disease. Importantly, the interaction between the inherited genetic background and some unhealthy dietary patterns has been postulated to have an essential role in the pathogenesis of NAFLD. Weight loss through lifestyle modifications is considered the cornerstone of the treatment for NAFLD and the inter-individual variability in the response to some dietary approaches may be conditioned by the presence of different single nucleotide polymorphisms. In this review, we summarize the current evidence on the influence of the association between genetic susceptibility and dietary habits in NAFLD pathophysiology, as well as the role of gene polymorphism in the response to lifestyle interventions and the potential interaction between nutritional genomics and other emerging therapies for NAFLD, such as bariatric surgery and several pharmacologic agents.

Sign in / Sign up

Export Citation Format

Share Document